MLANA and melanoma: CTC isolation from peripheral blood using a high-density dielectrophoretic microwell array, followed by labeling with melanoma-specific markers (MART-1 and/or gp100) and a leukocyte marker (CD45) of a few stages 0-III melanoma patients detected CTCs even in patients with early disease (stage 0 and I).